2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations.
Shin
Jonghan
J
Lee
Sang-Yoon
SY
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D000814:Aniline Compounds / Q000493:pharmacokinetics; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016874:Neurofibrillary Tangles / Q000000981:diagnostic imaging*; D009570:Nitriles / Q000493:pharmacokinetics*; D058225:Plaque, Amyloid / Q000000981:diagnostic imaging* / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000379:methods*; D013702:Temporal Lobe / Q000000981:diagnostic imaging* / Q000378:metabolism; D013844:Thiazoles / Q000493:pharmacokinetics
C444520:2-(1-(6-((2-fluoroethyl)(methyl)amino)-2-naphthyl)ethylidene)malononitrile; C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D009570:Nitriles; D013844:Thiazoles